15-48437376-G-A
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000138.5(FBN1):c.6325C>T(p.Gln2109Ter) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000000684 in 1,460,962 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000138.5 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
FBN1 | NM_000138.5 | c.6325C>T | p.Gln2109Ter | stop_gained | 52/66 | ENST00000316623.10 | NP_000129.3 | |
FBN1 | NM_001406716.1 | c.6325C>T | p.Gln2109Ter | stop_gained | 51/65 | NP_001393645.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
FBN1 | ENST00000316623.10 | c.6325C>T | p.Gln2109Ter | stop_gained | 52/66 | 1 | NM_000138.5 | ENSP00000325527 | P1 | |
FBN1 | ENST00000559133.6 | c.6325C>T | p.Gln2109Ter | stop_gained, NMD_transcript_variant | 52/67 | 1 | ENSP00000453958 | |||
FBN1 | ENST00000674301.2 | c.6325C>T | p.Gln2109Ter | stop_gained, NMD_transcript_variant | 52/68 | ENSP00000501333 | ||||
FBN1 | ENST00000537463.6 | c.*2088C>T | 3_prime_UTR_variant, NMD_transcript_variant | 27/31 | 5 | ENSP00000440294 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1460962Hom.: 0 Cov.: 31 AF XY: 0.00 AC XY: 0AN XY: 726858
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Marfan syndrome Pathogenic:2
Pathogenic, no assertion criteria provided | clinical testing | Center for Medical Genetics Ghent, University of Ghent | Nov 07, 2017 | - - |
Pathogenic, criteria provided, single submitter | research | Centre of Medical Genetics, University of Antwerp | Mar 01, 2021 | PM2, PVS1, PP4 - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Dec 20, 2017 | The Q2109X pathogenic variant in the FBN1 gene has been previously published in individuals who met the Ghent criteria for Marfan syndrome (Collod-Béroud et al., 2003; Stheneur et al., 2009; Baetens et al., 2011). Q2109X is predicted to cause loss of normal protein function either by protein truncation or nonsense-mediated mRNA decay. Other downstream nonsense variants in the FBN1 gene have been reported in Human Gene Mutation Database in association with Marfan syndrome (Stenson et al., 2014). Furthermore, the Q2109X variant is not observed in large population cohorts (Lek et al., 2016).In summary, Q2109X in the FBN1 gene is interpreted as a pathogenic variant. - |
Marfan syndrome;C4707243:Familial thoracic aortic aneurysm and aortic dissection Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 12, 2018 | This variant is not present in population databases (ExAC no frequency). For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in FBN1 are known to be pathogenic (PMID: 17657824, 19293843). This variant has been observed in individuals affected with Marfan syndrome, having been reported to be de novo in one of them (PMID: 19293843, 21542060). ClinVar contains an entry for this variant (Variation ID: 488820). This sequence change creates a premature translational stop signal (p.Gln2109*) in the FBN1 gene. It is expected to result in an absent or disrupted protein product. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at